Skip to main content

Orchid Shares Plummet 35 Percent on Widened Loss

NEW YORK, June 22 (GenomeWeb News) - Shares of Orchid Cellmark dropped $1.30, or 35.1 percent, to $2.40 in afternoon trading after the company said its first-quarter revenues declined 14 percent and losses increased.


As reported today in GenomeWeb News, Orchid's revenues declined to $12.6 million in the first quarter of 2006, from $14.7 million during the first quarter of 2005. Losses increased to $6.6 million from $1.7 million in the year-ago period. 

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.